SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation
A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)
Sponsor: Seikagaku Corporation
Listed as NCT00634946, this PHASE2/PHASE3 trial focuses on Lumbar Vertebra Hernia and remains completed. Sponsored by Seikagaku Corporation, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Apr 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seikagaku Corporation
For direct contact, visit the study record on ClinicalTrials.gov .